Patient experience in systemic lupus erythematosus: development of novel patient-reported symptom and patient-reported impact measures

S D Mathias; P Berry; J De Vries; K Pascoe; H H Colwell; D J Chang; A D Askanase

doi:10.1186/s41687-018-0028-7

Patient experience in systemic lupus erythematosus: development of novel patient-reported symptom and patient-reported impact measures

J Patient Rep Outcomes. 2017;2(1):11. doi: 10.1186/s41687-018-0028-7. Epub 2018 Feb 22.

Authors

S D Mathias¹, P Berry², J De Vries³, K Pascoe³, H H Colwell¹, D J Chang², A D Askanase⁴

Affiliations

¹ Health Outcomes Solutions, PO Box 2343, Winter Park, FL 32790 USA.
² 2GlaxoSmithKline, Philadelphia, PA USA.
³ 3GlaxoSmithKline, London, UK.
⁴ 4Columbia University Medical Center, New York, NY USA.

Abstract

Background: Comprehensive assessment of systemic lupus erythematosus (SLE) and its treatment requires patient-reported outcome (PRO) measures to capture impacts and fluctuating symptoms. The objective of this study was to develop PROs, in accordance with the Food and Drug Administration (FDA) PRO Guidance, to assess fluctuations in SLE symptoms and its impact.

Methods: Following independent review board approval, six US rheumatology practices recruited patients with SLE to participate in concept elicitation (CE) interviews, in order to identify important SLE symptoms and their impacts. The SLE Symptom Severity Diary (SSD) and SLE Impact Questionnaire (SIQ) were drafted based on CE interview results and clinician input. The PROs were revised based on patient feedback from cognitive debriefing (CD) interviews, clinician feedback, and a translatability assessment.

Results: Forty-one patients completed CE interviews. Commonly-reported symptoms included fatigue (98%), joint pain (93%), and rash (88%). The most frequently reported impact was difficulty with chores/housework (61%). Eighteen patients completed CD interviews. The PROs were considered comprehensive, clear, and relevant.The SSD contains 17 items assessing energy/vitality, joint and muscle pain/stiffness/swelling, flu-like symptoms, cognition, numbness/tingling, skin symptoms and hair loss using an 11-point numeric response scale and a 24-h recall period (with the exception of hair loss). It also evaluates steroid status and dose. The SIQ contains 50 items, uses a 5-point Likert scale and a 7-day recall period, to assess disease impacts including patients' ability to make plans, work, and physical/social/emotional functioning.

Conclusion: The SSD and SIQ are comprehensive SLE-specific PROs developed in accordance with the FDA PRO Guidance. Following assessment of their measurement properties, they may be useful in clinical studies and clinical practice to measure fluctuations in, and the impact of, symptoms in patients with SLE.

Keywords: Patient experience; Patient-reported outcomes; Questionnaire; Symptoms; Systemic lupus erythematosus.